+

TN2009000163A1 - Compounds and compositions as protein kinase inibitors - Google Patents

Compounds and compositions as protein kinase inibitors

Info

Publication number
TN2009000163A1
TN2009000163A1 TNP2009000163A TN2009000163A TN2009000163A1 TN 2009000163 A1 TN2009000163 A1 TN 2009000163A1 TN P2009000163 A TNP2009000163 A TN P2009000163A TN 2009000163 A TN2009000163 A TN 2009000163A TN 2009000163 A1 TN2009000163 A1 TN 2009000163A1
Authority
TN
Tunisia
Prior art keywords
compounds
compositions
inibitors
protein kinase
disorders
Prior art date
Application number
TNP2009000163A
Other languages
English (en)
Inventor
Donatella Chianelli
Xiaolin Li
Xiaodong Liu
Jon Loren
Valentina Molteni
Juliet Nabakka
Laszlo Revesz
Lawrence B Perez
Clinton Brooks
Wojciech Wrona
Paul W Manley
Breiteinstei
Original Assignee
Norvartis Ag
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norvartis Ag, Irm Llc filed Critical Norvartis Ag
Publication of TN2009000163A1 publication Critical patent/TN2009000163A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
TNP2009000163A 2006-11-03 2009-04-29 Compounds and compositions as protein kinase inibitors TN2009000163A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86437806P 2006-11-03 2006-11-03
PCT/US2007/083543 WO2008058037A1 (fr) 2006-11-03 2007-11-02 Composés et compositions en tant qu'inhibiteurs des protéines kinases

Publications (1)

Publication Number Publication Date
TN2009000163A1 true TN2009000163A1 (en) 2010-10-18

Family

ID=39119736

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000163A TN2009000163A1 (en) 2006-11-03 2009-04-29 Compounds and compositions as protein kinase inibitors

Country Status (20)

Country Link
US (1) US20100048539A1 (fr)
EP (1) EP2079729A1 (fr)
JP (1) JP2010509349A (fr)
KR (2) KR20120049397A (fr)
CN (1) CN101622244A (fr)
AU (1) AU2007317349B2 (fr)
BR (1) BRPI0718677A2 (fr)
CA (1) CA2668190A1 (fr)
CO (1) CO6241115A2 (fr)
CR (1) CR10755A (fr)
EA (1) EA200970447A1 (fr)
EC (1) ECSP099378A (fr)
IL (1) IL198315A0 (fr)
MA (1) MA30906B1 (fr)
MX (1) MX2009004716A (fr)
NO (1) NO20092138L (fr)
RU (1) RU2009120882A (fr)
SM (1) SMAP200900031A (fr)
TN (1) TN2009000163A1 (fr)
WO (1) WO2008058037A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
ES2390227T3 (es) 2004-09-09 2012-11-07 Natco Pharma Limited Nuevos derivados de fenilaminopirimidina como inhibidores de la BCR-ABL kinasa
DK2035369T3 (da) 2006-07-05 2014-10-06 Fibrotech Therapeutics Pty Ltd Terapeutiske
JP5160637B2 (ja) 2007-05-04 2013-03-13 アイアールエム・リミテッド・ライアビリティ・カンパニー ｃ−ｋｉｔおよびＰＤＧＦＲキナーゼインヒビターとしての化合物および組成物
EP2152079A4 (fr) * 2007-06-04 2011-03-09 Avila Therapeutics Inc Composés hétérocycliques et utilisations de ceux-ci
AU2008289135B2 (en) 2007-08-22 2012-02-23 Irm Llc 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
CN101784530A (zh) 2007-08-22 2010-07-21 Irm责任有限公司 作为激酶抑制剂的5-(4-(卤代烷氧基)苯基)嘧啶-2-胺化合物和组合物
MX2011001668A (es) * 2008-08-13 2011-03-25 Novartis Ag Tratamiento de hipertension arterial pulmonar.
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
US20120015968A1 (en) * 2009-03-06 2012-01-19 Novartis Ag Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper-and sterile alpha motif-containing kinase (zak)
EP2491030B1 (fr) 2009-10-22 2015-07-15 Fibrotech Therapeutics PTY LTD Analogues à cycles condensés d'agents anti-fibrotiques
EP2566869B1 (fr) * 2010-05-07 2016-03-02 Gilead Connecticut, Inc. Composés de pyridone et d'aza-pyridone et leurs procédés d'utilisation
JP5855095B2 (ja) 2010-06-07 2016-02-09 ノボメディックス, エルエルシーNovomedix, Llc フラニル化合物およびその使用
EA201390717A1 (ru) * 2010-11-17 2013-10-30 Новартис Аг 3-(аминоарил)пиридиновые соединения
WO2013022766A1 (fr) 2011-08-05 2013-02-14 Flynn Gary A Préparation et procédés d'utilisation d'ortho-aryle hétéroaryle à 5 chaînons -carboxamide contenant des inhibiteurs de kinases multicibles
US9199981B2 (en) * 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
JP2014525447A (ja) * 2011-09-01 2014-09-29 アイアールエム・リミテッド・ライアビリティ・カンパニー ｃ−Ｋｉｔキナーゼ阻害剤としての化合物および組成物
KR101962495B1 (ko) 2011-09-01 2019-03-26 노파르티스 아게 C-kit 키나제 억제제로서의 화합물 및 조성물
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014170350A1 (fr) * 2013-04-17 2014-10-23 Albert Ludwigs Universität Freiburg Composés destinés à être utilisés comme inhibiteurs de bromodomaine
CN103288804A (zh) * 2013-05-24 2013-09-11 苏州明锐医药科技有限公司 一种尼洛替尼的制备方法
BR112015030399B8 (pt) 2013-06-05 2023-01-10 C&C Res Lab Derivados heterocíclicos, uso dos referidos derivados e composição farmacêutica para a prevenção ou tratamento de doenças associadas com a ativação da proteína stat3
US20170000784A1 (en) * 2013-12-08 2017-01-05 Van Andel Research Institute Autophagy Inhibitors
LT3113772T (lt) 2014-03-07 2020-12-28 Biocryst Pharmaceuticals, Inc. Trifluormetilo pakeistieji pirazolai kaip žmogaus plazmos kalikreino inhibitoriai
CN105085489B (zh) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CN106187995A (zh) * 2015-05-05 2016-12-07 天津国际生物医药联合研究院 含酰胺键杂环类化合物及其制备方法和应用
WO2017040194A1 (fr) * 2015-09-04 2017-03-09 Dow Agrosciences Llc Molécules présentant une utilité en tant que pesticide, et leurs intermédiaires, compositions et procédés
JP2019515643A (ja) * 2015-09-23 2019-06-13 ミネルバ バイオテクノロジーズ コーポレーション 幹細胞分化剤のスクリーニング方法
SI3426243T1 (sl) 2016-03-09 2021-11-30 Raze Therapeutics, Inc. Zaviralci 3-fosfoglicerat dehidrogenaze in uporabe le-teh
US11014882B2 (en) * 2016-03-09 2021-05-25 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
CN105974131B (zh) * 2016-06-16 2017-12-26 武汉大学 c‑Kit作为药物成瘾治疗靶点的应用
MX392368B (es) * 2016-12-15 2025-03-24 Univ California Composiciones y metodos para el tratamiento del cancer
JP7185631B2 (ja) 2017-02-03 2022-12-07 サータ セラピューティクス プロプライエタリー リミテッド 抗線維化化合物
JP6994715B2 (ja) * 2017-10-04 2022-02-04 国立大学法人京都大学 Ｂｃｒ－Ａｂｌタンパク質イメージング用分子プローブ
CN108187052B (zh) * 2018-02-05 2021-06-08 苏州大学 Akt抑制剂在制备治疗血小板数量减少相关疾病药物中的用途
US11767319B2 (en) 2020-07-15 2023-09-26 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
JP7511294B2 (ja) * 2020-08-11 2024-07-05 ホーナン メディノ ファーマシューティカル テクノロジー カンパニー リミテッド Ｆｇｆｒ阻害剤化合物及びその使用
US11629143B2 (en) 2020-10-01 2023-04-18 Vibliome Therapeutics, Llc HipK4 inhibitors and uses thereof
JP2023551434A (ja) 2020-11-19 2023-12-08 サード ハーモニック バイオ， インコーポレイテッド 選択的ｃ－ｋｉｔキナーゼ阻害剤の医薬組成物ならびにその作製および使用のための方法
CN113797345B (zh) * 2021-10-22 2023-05-16 北京大学人民医院 糖皮质激素与糖酵解调节剂在制备急性移植物抗宿主病的药物中的应用
AU2023262139A1 (en) * 2022-04-27 2024-11-28 Mrja Therapeutics, Inc. Certain chemical entities, compositions, and methods
WO2024123966A1 (fr) * 2022-12-07 2024-06-13 Third Harmonic Bio, Inc. Composés et compositions utilisés en tant qu'inhibiteurs de c-kit kinase

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721609A3 (fr) * 2001-05-16 2007-01-31 GPC Biotech AG Dérivés de pyridylpyrimidine utilisés comme composés actifs contre des infections et des maladies à prions
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds
ES2390227T3 (es) * 2004-09-09 2012-11-07 Natco Pharma Limited Nuevos derivados de fenilaminopirimidina como inhibidores de la BCR-ABL kinasa
EP1836173A4 (fr) * 2004-12-23 2009-07-08 Deciphera Pharmaceuticals Llc Medicaments anti-inflammatoires
EP1835934A4 (fr) * 2004-12-23 2010-07-28 Deciphera Pharmaceuticals Llc Modulateurs d'enzymes et traitements
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법

Also Published As

Publication number Publication date
BRPI0718677A2 (pt) 2013-11-26
SMAP200900031A (it) 2009-07-14
AU2007317349A1 (en) 2008-05-15
MA30906B1 (fr) 2009-11-02
CR10755A (es) 2009-06-04
CN101622244A (zh) 2010-01-06
KR20120049397A (ko) 2012-05-16
KR20090075889A (ko) 2009-07-09
CA2668190A1 (fr) 2008-05-15
RU2009120882A (ru) 2010-12-10
IL198315A0 (en) 2010-02-17
US20100048539A1 (en) 2010-02-25
NO20092138L (no) 2009-07-13
JP2010509349A (ja) 2010-03-25
EP2079729A1 (fr) 2009-07-22
ECSP099378A (es) 2009-07-31
WO2008058037A1 (fr) 2008-05-15
CO6241115A2 (es) 2011-01-20
AU2007317349B2 (en) 2011-10-20
MX2009004716A (es) 2009-07-17
EA200970447A1 (ru) 2009-10-30

Similar Documents

Publication Publication Date Title
TN2009000163A1 (en) Compounds and compositions as protein kinase inibitors
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
MX2009011950A (es) Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
WO2009097287A9 (fr) Composés et compositions comme inhibiteurs de kinases
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
TN2014000068A1 (en) Compounds and compositions as c-kit kinase inhibitors
TN2014000061A1 (en) COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
MX2009006170A (es) Compuestos y composiciones como inhibidores de cinasa.
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
BRPI0814065B8 (pt) derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase
BR112014004465A2 (pt) compostos e composições como inibidores de pdgfr cinase
WO2011014795A3 (fr) Composés et compositions pouvant servir d'inhibiteurs de la kinase syk
MX2009000333A (es) Pirrilopirimidinas para composiciones farmaceuticas.
UA103617C2 (ru) Производные тиенопиридона как активаторы амр-активированной протеинкиназы (амрк)
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
MX2010010877A (es) Compuestos y composiciones como inhibidores de itpkb.
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
EA200901656A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ ITPKb
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载